Epizyme (EPZM) Revised Celgene Agreement 'Net Positive', Mizuho Securities Says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Epizyme Announces Extension of Celgene Research Collaboration
July 9, 2015 7:00 AM EDTCollaboration to focus on three first-in-class preclinical epigenetic targets Epizyme to receive $10 million extension fee payment and up to $610 million in potential milestones Epizyme extends cash runway through at least the end of the second quarter of 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, today announced that it has amended and restated its agreement with Celgene Corporation to extend the research collaboration... More
